Studies
Current Endometriosis Research
Understanding endometriosis requires access to reliable, up-to-date research. This section is for those who want to explore the evidence behind current knowledge — including ongoing and completed studies, opportunities to participate in research, and a structured view of how the scientific landscape is developing.
Do you want to:
Studies you can join
Clinical studies seeking participants
EndoSolve
OnaWave Medical is developing a novel, non-invasive and painless method for faster diagnosis of endometriosis through analysis of subtle bioelectric rhythms in the pelvis. Built on research from University of Galway and supported by the European Innovation Council.
Endogreet
A potential non-hormonal treatment approach using Tigovit, a green tea extract, in a randomized, double-blind, placebo-controlled study at MedUni Vienna. Green tea extract has shown promise in reducing both pain and inflammation around endometriosis lesions.
131 publications
Variation in endometriosis aetiology, potential impact on lesion heterogeneity and the consequences for research and treatment
PII: S2949838426000022Review proposing that endometriosis lesions develop through multiple routes: retrograde menstruation, embryonic stem cell remnants, stem cell recruitment, and genetic/epigenetic modifications. Different genetic risk combinations may predispose individuals to different routes of lesion development, contributing to disease heterogeneity. Advocates for molecular profiling and patient-derived organoid models to advance research.
Jun 1, 2026
Transferrin participates in the pathogenesis of endometriosis by influencing the proliferation, migration and apoptosis of endometrial cells
DOI: 10.64898/2026.03.13.711522Preprint study showing elevated transferrin and its receptor in endometriotic cells alongside reduced antioxidant capacity. Experimental knockdown of transferrin suppressed cell proliferation and migration while increasing apoptosis, implicating the transferrin/ferroptosis axis in disease pathogenesis. Findings are preliminary and have not yet undergone peer review.
Mar 16, 2026
Precision Medical Management of Endometriosis: Neuroimmune Pathophysiology, Pain Phenotyping and Emerging Target Therapies
DOI: 10.5772/intechopen.1014711Book chapter synthesizing precision medicine approaches to endometriosis, integrating pain phenotyping, molecular and inflammatory biomarkers, and mechanisms of treatment resistance. The authors review targeted pharmacologic strategies including neuromodulators, selective progesterone receptor modulators, immunomodulatory and anti-fibrotic agents, and non-hormonal therapies under investigation. The chapter provides a mechanism-based framework for individualized treatment grounded in neuroinflammation, peripheral and central sensitization, and immune dysregulation.
Mar 2, 2026
Precision-based solutions for endometriosis: Integrating immunomics and drug repositioning strategies
PMID: 41702084Review characterizing endometriosis as an estrogen-dependent chronic inflammatory disorder driven by immune cell dysfunction and immune evasion. Proposes a drug screening framework based on the immune microenvironment, integrating immunomics with drug repositioning strategies. Identifies immune-modulating therapies, anti-inflammatory agents, and epigenetic modulators as priority directions for precision-based treatment.
Feb 16, 2026
Gut Microbiota Alterations and Reproductive Tract Dysbiosis in Endometriosis: A Systematic Review
DOI: 10.3390/medicina62020351Systematic review examining the dual role of gut microbiota in endometriosis: on one hand reflecting underlying disease processes, as well as potentially influencing disease progression in parallel. Microbial alterations are associated with changes in estrogen metabolism, immune modulation, and metabolic pathways that may favor chronic inflammation and sustained lesion activity. While microbial signatures have been identified, causality remains unclear. Authors call for mechanistic studies to assess whether targeting gut microbiota could serve as an adjunctive diagnostic or therapeutic approach.
Feb 10, 2026
Gut microbiota as a key regulator in endometriosis: mechanisms, therapeutic opportunities, and future perspectives
DOI: 10.3389/fcimb.2025.1730739Review synthesizing evidence that gut microbiota dysbiosis drives endometriosis through three pathways: immunoinflammatory dysregulation via increased LPS levels, enhanced estrogen metabolism, and aberrant lipid metabolism. Animal studies confirm causality - antibiotic-treated mice showed reduced lesions while fecal transplants from healthy mice prevented disease. Highlights dietary modification, probiotics, and fecal microbiota transplantation as therapeutic opportunities.
Jan 30, 2026
Cannabis-based medicines for chronic neuropathic pain in adults
PMID: 41548880Cochrane systematic review analyzing 21 randomized controlled trials (2,187 adults) on cannabis-based medicines for chronic neuropathic pain. Notably, only 4 of 21 studies met the EMA's recommended minimum of 12 weeks for chronic pain conditions. Across THC-dominant, CBD-dominant, and combined formulations (sprays, oral, inhaled, topical), no reliable evidence was found that cannabis reduces neuropathic pain more effectively than placebo. For THC/CBD combinations, 268 vs 197 per 1,000 patients reported "much improved" - a small difference with low certainty. Neurological side effects (dizziness, somnolence, cognitive impairment) and psychiatric events were more frequent with active treatment. Evidence quality rated very low per GRADE criteria; authors call for larger, longer trials with broader inclusion criteria.
Jan 19, 2026
Endometriosis as a Systemic and Complex Disease: Toward Phenotype-Based Classification and Personalized Therapy
PMID: 41596555This review reframes endometriosis as a chronic, systemic, and multifactorial inflammatory disorder rather than a purely pelvic condition, showing how ectopic tissue interacts with the immune system and distant organs. Circulating biomarkers including microRNAs, proteins, and extracellular vesicles show potential for diagnosis and monitoring. The authors argue that conventional hormonal therapies are insufficient and call for a systems medicine approach targeting immune modulation and epigenetic regulators.
Jan 16, 2026
Parthenolide attenuated the endometriosis-like lesions by activating autophagy and suppressing NLRP3 inflammasome activity
PMCID: PMC12867106Preclinical study examining parthenolide (PTL), a natural compound from feverfew. In cell models, PTL inhibited NLRP3 inflammasome activation and inflammatory markers (IL-1β, GSDMD) while enhancing autophagy. In mice, PTL significantly reduced the number, surface area, and weight of ectopic lesions. The dual mechanism — activating autophagy via AMPK/ULK1 pathway while inhibiting NLRP3 inflammasome and its downstream effectors — suggests potential as a non-hormonal therapy with fewer side effects than conventional hormone-based treatments.
Jan 1, 2026
Endopaedia Knowledge Map
Visual representation of curated scientific papers across research categories
Bubble size reflects number of papers. Double border indicates recent additions.
Mechanisms
38 papers(+2 new)
Natural Compounds
36 papers
Pain & Sensitization
17 papers
Drugs & Pharmaceuticals
15 papers
Comorbidities
12 papers
Diagnostics & Biomarkers
11 papers
Epidemiology
10 papers
Genetics & Genomics
8 papers
Interventions
8 papers
Surgical Techniques
7 papers
Microbiome
6 papers
Devices & Physical Care
2 papers
Fertility & Reproduction
1 paper
Open Knowledge Map
Interactive overview of global publications around the keywords endo & inflammation
Powered by Open Knowledge Maps